PLSE (Pulse Biosciences) Net Income From Continuing Operations: $-80.06 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLSE Pulse Biosciences Inc PLSE
31 GF Score
Price $48.79
! 4 Warning Signs
View Full Analysis

What is Pulse Biosciences Net Income From Continuing Operations?

Pulse Biosciences PLSE -8.17% 31 Net Income From Continuing Operations is $-80.06 Mil as of Jun. 2026. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Pulse Biosciences's net income from continuing operations for the three months ended in Jun. 2026 was $-24.66 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-80.06 Mil.

Pulse Biosciences Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Pulse Biosciences's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulse Biosciences Net Income From Continuing Operations Chart

Pulse Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -63.66 -58.51 -42.21 -53.59 -72.78

Pulse Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.17 -19.39 -17.43 -18.58 -24.66
PLSE
31GF Score
Pulse Biosciences Inc PLSE
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pulse Biosciences Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-80.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $-80.06 Mil mean?
Pulse Biosciences (PLSE) has a Net Income From Continuing Operations of $-80.06 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Pulse Biosciences and its competitors.
Is Pulse Biosciences' Net Income From Continuing Operations too high?
Pulse Biosciences' current Net Income From Continuing Operations is $-80.06 Mil. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' Net Income From Continuing Operations compare to WRBY and ATRC?
Pulse Biosciences' Net Income From Continuing Operations of $-80.06 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Medical Devices & Instruments company?
A good Net Income From Continuing Operations depends on the Medical Devices & Instruments industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Pulse Biosciences and its competitors. Pulse Biosciences's current Net Income From Continuing Operations is $-80.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current Net Income From Continuing Operations of $-80.06 Mil. The current Net Income From Continuing Operations is $-80.06 Mil. Pulse Biosciences' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current Net Income From Continuing Operations is $-80.06 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pulse Biosciences Business Description

Other Exchanges 6L8:Germany
Address 601 Brickell Key Drive, Suite 1080, Miami, FL, USA, 33131
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
31GF Score

Get the complete analysis for PLSE

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$48.79
Price